Safety Of Injectables: Ensuring Purity Via Endotoxin Testing

Ensuring the safety of injectable and infused drugs depends on accurate detection of bacterial endotoxins, contaminants capable of causing severe inflammatory reactions in patients. For decades, endotoxin testing has been an essential component of pharmaceutical quality control, evolving from the rabbit pyrogen test to the limulus amebocyte lysate (LAL) assay, which uses horseshoe crab blood cells to detect endotoxins with high sensitivity. However, increasing global demand has raised concerns about the sustainability, consistency, and supply of animal-derived reagents.

Recombinant factor C (RFC) provides a modern, scientifically validated alternative by using a synthetic version of the endotoxin-sensitive protein that drives the LAL reaction. When endotoxins are present, RFC produces a measurable fluorescent signal without relying on animal-derived materials. Compared with LAL, RFC offers improved consistency, reduced assay interference, and a more sustainable supply chain. With USP Chapter 86 recognizing non-animal endotoxin testing methods, RFC is positioned to support the future of safe, reliable pharmaceutical quality testing.